Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 7 for GlaxoSmithKline Consumer Healthcare Holdings LLC.
GlaxoSmithKline Consumer Healthcare Holdings LLC: 0 warning letters, 7 recalls, 0 approval records, 0 Form 483s.
Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.
Side by side
GlaxoSmithKline Consumer Healthcare Holdings LLC — Warning letters0
Philips North America — Warning letters0
GlaxoSmithKline Consumer Healthcare Holdings LLC — Recalls7
Philips North America — Recalls355
GlaxoSmithKline Consumer Healthcare Holdings LLC — Approval records0
Philips North America — Approval records0
GlaxoSmithKline Consumer Healthcare Holdings LLC — Form 483s0
Philips North America — Form 483s0
Timeline
GlaxoSmithKline Consumer Healthcare Holdings LLC
Most recent FDA action: November 8, 2023
Full history →Cite this comparison
Pre-formatted for a story, footnote, or reference list:
"GlaxoSmithKline Consumer Healthcare Holdings LLC vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed July 17, 2026. https://argushq.ai/compare/glaxosmithkline-consumer-healthcare-holdings-llc-vs-philips-north-america
Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗